The BeLimumab Antiphospholipid Syndrome Trial (BLAST)
Status:
Recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
AIM: The primary objective of the BeLimumab Antiphospholipid Syndrome Trial (BLAST) is to
evaluate the safety and tolerability of belimumab for up to 24 months in patients with
persistent aPL positivity and clinical features attributable to aPL that are resistant to
warfarin and/or heparin.